AZN vs MASS

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

The company exhibits severe financial fragility, highlighted by a Piotroski F-Score of 1/9, indicating a critical lack of fundamental strength. While the balance sheet shows strong liquidity (Current Ratio 4.24) and minimal debt (Debt/Equity 0.03), these are offset by negative revenue growth (-7.70% YoY) and persistent operating losses. Insider sentiment is strongly bearish, with the CEO, CFO, and Directors selling shares amidst a long-term price collapse of 85.9% over five years. The disconnect between the high reported profit margin and the negative operating margin suggests non-operational gains rather than a sustainable business model.